Cancer Supportive Care Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

Cancer Supportive Care Drugs Market By Drug Class (Antiemetics, Antidiarrheals, Anti-Infective Drugs, Granulocyte Colony Stimulating Factors (G-CSF), Antacids, Antimetabolites, Cytoprotectants, Nsaids, Opioid Analgesics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Application (Breast Cancer, Blood Cancer, Prostate Cancer, Lung Cancer, And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a significant CAGR forecast till 2030 owing to the increasing number of cancer cases globally and rising adverse effect associated with cancer treatment.

The global cancer supportive care drugs market is estimated to grow at a CAGR of 2.08% during the forecast period from 2024 to 2030 to reach USD 16.8 billion by 2030. The demand for cancer supportive care drugs is primarily being driven by the increasing number of cancer cases globally. The rising adverse effects associated with cancer treatment which requires supportive care drugs for the treatment of adverse effects induced by cancer drugs such as chemotherapy and government support for cancer treatment are some of the key factors that are responsible for contributing to the positive growth of the cancer supportive care drugs market during the forecast period from 2024 to 2030.

Cancer Supportive Care Drugs Market Dynamics:

According to the data provided by the World Health Organization (WHO) in February 2023, it was estimated that in 2022, there were approximately 20 million new cases of cancer diagnosed and this number is estimated to increase to 35 million by 2050. The projected number of individuals surviving at least five years after a cancer diagnosis was estimated at 53.5 million. Cancer affects roughly one in five individuals during their lifetime, with mortality rates of approximately 1 in 9 for men and 1 in 12 for women.

In March 2023, Cancer Research UK, a cancer research organization based in the United Kingdom, reported that there were approximately 18.1 million new cancer cases globally in 2020. It is estimated that by 2040, the global annual incidence of new cancer cases will rise to 28 million. Of the cases diagnosed in 2020, 8.8 million (48%) were in females, while 9.3 million (52%) were in males.

According to the American Cancer Society (2020) data, chemotherapy commonly affects blood-forming cells in bone marrow and cells in the mouth, digestive tract, and reproductive system. The most frequent side effects include nausea, vomiting, fatigue, dry mouth, and loss of blood cells. In June 2022, a USFDA report revealed findings from a clinical trial indicating a potentially higher risk of mortality associated with Copiktra (duvelisib) compared to an alternative medication for treating a chronic hematologic malignancy. The trial also found that Copiktra was linked to a greater risk of serious side effects, such as infections, diarrhea, and intestinal inflammation.

Cancer supportive care drugs are essential for managing the symptoms and side effects associated with cancer and its treatment. These medications aim to enhance the quality of life for cancer patients by alleviating discomfort and addressing complications arising from cancer or its treatments. With the increasing number of cancer patients, the demand for cancer supportive care drugs is expected to rise, driving growth in the overall cancer supportive care drugs market.

In 2022, the Government of Australia invested AUD 893.5 million in cancer testing, prevention, and treatment. This funding was used to develop state-of-the-art cancer treatment centers aimed at saving the lives of patients with life-threatening cancers. According to a report published by the UK Parliament in January 2024, nearly EUR 122 million (USD 132.65 million) was allocated for cancer research in the fiscal year 2022-23 through the National Institute for Health and Care Research. Additionally, UK Research and Innovation commits approximately £200 million (USD 217.46 million) annually to support cancer research initiatives.

Government funding for the treatment of cancer can significantly drive the growth of the cancer supportive care drugs market by increasing access to these essential medications. When governments allocate financial resources towards cancer care, they often include provisions for supportive care to manage the side effects of cancer treatments, such as pain, nausea, and anemia. This funding can lead to broader insurance coverage and reimbursement for supportive care drugs, making them more affordable and accessible to a larger patient population.

Additionally, government investment in healthcare infrastructure and research can spur innovation and development of new supportive care therapies, further expanding the market. Enhanced funding also enables healthcare providers to implement comprehensive cancer care protocols, which emphasize the importance of supportive medications in improving patient outcomes and quality of life, thereby boosting demand for these drugs.

However, the stringent regulatory guidelines, and the lack of healthcare infrastructure in poor countries, among others are some of the key constraints that may limit the growth of the cancer supportive care drugs market.

Cancer Supportive Care Drugs Market Segment Analysis:

Cancer Supportive Care Drugs Market By Drug Class (Antiemetics, Antidiarrheals, Anti-Infective Drugs, Granulocyte Colony Stimulating Factors, Antacids, Antimetabolites, Cytoprotectants, NSAID’s, Opioid Analgesics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Application (Breast Cancer, Blood Cancer, Prostate Cancer, Lung Cancer, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the drug class segment of the cancer supportive care drugs market, the antiemetics category is estimated to amass a significant revenue share in the cancer supportive care drugs market in 2023. This is attributed to the growing use of antiemetics drugs for the treatment of nausea and vomiting occurred during cancer treatment. Antiemetic drugs such as ondansetron, palonosetron, fosnetupitant, etc. are the most commonly used medicines. Preventing the nausea and vomiting often induced by cancer treatmenmt is considered a paramount clinical goal and Antiemetic drugs play a crucial role in mitigating these adverse effects.

In January 2023, Glenmark Pharmaceuticals Ltd. Launched AKYNZEO in India for the prevention of chemotherapy-induced nausea and vomiting (CINV), under a licensing agreement with Helsinn Healthcare SA. This drug provides treatment for acute and delayed phases of chemotherapy-induced nausea and vomiting.

In May 2022, Taiho Pharmaceutical Co., Ltd. announced that it had launched Arokaris® I.V. infusion in Japan. It is a selective NK1 receptor antagonist antiemetic drug developed for the treatment of chemotherapy-induced nausea and vomiting. It is a phosphorylated pro-drug preparation (injection) that is converted to netupitant, the active component.

Therefore, the growing use of antiemetic drugs to prevent nausea and vomiting in patients undergoing cancer therapy will contribute to the growth of the segment, thereby driving the growth of the overall cancer supportive care drugs market during the forecast period.

North America Is Expected To Dominate The Overall Cancer Supportive Care Drugs Market:

North America is estimated to account for the highest market share of the cancer supportive care drugs market in 2023, out of all regions. This is due to the rising number of cancer cases in the region and the growing geriatric population is some of the key factors driving the growth of the cancer supportive care drugs market in North America.

According to the American Cancer Society's Cancer Facts & Figures 2024, nearly 2 million new cancer cases are expected to be diagnosed in the United States in 2024, up from 1.9 million in 2023. Data published by the National Cancer Institute in May 2024 indicates that as of January 2022, there were an estimated 18.1 million cancer survivors in the United States, accounting for roughly 5.4% of the population. Projections suggest that the number of cancer survivors will grow by 24.4%, reaching 22.5 million by 2032 and 26 million by 2040.

In January 2024, the Population Reference Bureau reported that the number of Americans aged 65 and above is projected to grow significantly, from 58 million in 2022 to 82 million by 2050, a 47% increase. Additionally, the proportion of this age group within the total population is expected to rise from 17% to 23%. Consequently, the increasing number of cancer cases and the rising geriatric population are key factors driving the growth of the cancer supportive care drugs market in North America.

Cancer Supportive Care Drugs Market Key Players:

Some of the key market players operating in the cancer supportive care drugs market include Helsinn Healthcare SA, Merck & Co., Inc., Sanofi, Pfizer Inc., GSK plc, F. Hoffmann-La Roche Ltd., Amgen Inc., Novartis AG, Viatris Inc., Nimbus Therapeutics, Gilead Sciences, Inc., Eli Lilly and Company, Moderna, Inc., AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Otsuka Holdings Co., Ltd., Affimed GmbH, Bristol-Myers Squibb Company, and others.

Recent Developmental Activities In The Cancer Supportive Care Drugs Market:

• In May 2023, RedHill Biopharma Ltd. Announced that it has patents in both the European Union and the United States for RHB-102 (BEKINDA). RHB-102 I developed for the treatment of chemotherapy and radiotherapy induced nausea and vomiting.
• In January 2023, Helsinn Healthcare SA and Immedica Pharma AB announced that both companies have entered an exclusive long-term agreement for the commercialization of two cancer supportive care products which is Akynzeo and Aloxi, in core European markets, aimed at preventing chemotherapy-induced nausea and vomiting (CINV).

Key Takeaways From The Cancer Supportive Care Drugs Market Report Study

• Market size analysis for current Cancer Supportive Care Drugs Market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global Cancer Supportive Care Drugs market.
• Various opportunities available for the other competitors in the Cancer Supportive Care Drugs Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current Cancer Supportive Care Drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Cancer Supportive Care Drugs market growth in the coming future?

Target Audience Who Can Be Benefited From This Cancer Supportive Care Drugs Market Report Study

• Cancer Supportive Care Drugs product providers
• Research organizations and consulting companies
• Cancer Supportive Care Drugs related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Cancer Supportive Care Drugs
• Various end-users who want to know more about the Cancer Supportive Care Drugs Market and the latest technological developments in the Cancer Supportive Care Drugs Market.
• Frequently Asked Questions For The Cancer Supportive Care Drugs Market:

1. What are Cancer Supportive Care Drugs?

Cancer Supportive Care Drugs are medicines strategically formulated to address and alleviate the symptoms and adverse effects accompanying cancer and its therapies. These medications are tailored to enhance the well-being and comfort of cancer patients by managing issues such as pain, nausea, fatigue, and psychological distress, while also addressing potential complications like anemia, infection, and bone health.

2. What is the market for Cancer Supportive Care Drugs?

The global cancer supportive care drugs market is estimated to grow at a CAGR of 2.08% during the forecast period from 2024 to 2030 to reach USD 16.8 billion by 2030.

3. What are the drivers for the global Cancer Supportive Care Drugs market?

The demand for cancer supportive care drugs is primarily being driven by the increasing number of cancer cases globally. The rising adverse effects associated with cancer treatment which requires supportive care drugs for the treatment of adverse effects induced by cancer drugs such as chemotherapy and government support for cancer treatment are some of the key factors that are responsible for contributing to the positive growth of the cancer supportive care drugs market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the global Cancer Supportive Care Drugs market?

Some of the key market players operating in the cancer supportive care drugs include Helsinn Healthcare SA, Merck & Co., Inc., Sanofi, Pfizer Inc., GSK plc, F. Hoffmann-La Roche Ltd., Amgen Inc., Novartis AG, Viatris Inc., Nimbus Therapeutics, Gilead Sciences, Inc., Eli Lilly and Company, Moderna, Inc., AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Otsuka Holdings Co., Ltd., Affimed GmbH, Bristol-Myers Squibb Company, and others.

5. Which region has the highest share in the global Cancer Supportive Care Drugs market?

North America is estimated to account for the highest market share of the cancer supportive care drugs market in 2023, out of all regions. This is due to the rising number of cancer cases in the region and the growing geriatric population is some of the key factors driving the growth of the cancer supportive care drugs market in North America.


This product will be delivered within 2 business days.